Post by account_disabled on Mar 6, 2024 5:36:57 GMT
If it is diagnosed that the Distinction must be withdrawn, the Cemefi Corporate Social Responsibility Committee will be in charge of announcing this situation.
"If a judicial process is presented, it is expected to be concluded, subsequently, Cemefi dialogues with the company, knows in depth the problem in question and on occasions, it has been suggested to the company to stop using the Distinctive" it was reported.
there is any review to remove the ESR Distinction from PiSA Farmacéutica.
PiSA Farmacéutica is a 75-year-old Mexican Chile Mobile Number List corporation that is the largest drug manufacturer in the country, with an annual production of more than one billion units, such as diabetes tablets. In addition to being the only producer of the drug methotrexate, used in children's chemotherapy.
This company also owns Dimesa, one of the three largest distributors in the country and recently accused of abusive practices by monopolizing – along with two other companies – 60% of IMSS and ISSSTE purchases during the previous six-year term.
CSR or not CSR?
The 2017 Sustainability Report of PiSA Farmacéutica, the most recent edition that is disseminated to the public, indicates the company as a corporation that works for its continuous improvement, establishing projects that promote responsible management of the impact of its operation, in an economic aspect, social and environmental.
This Report frames its corporate social responsibility (CSR) actions with brief information, social impact figures, investments and volunteering, in a very general way and without clear details.
It is reported, for example, that the company has a CSR Committee that is made up of small committees that represent the five areas in which they work, which are aligned with those evaluated by Cemefi: business ethics, quality of life in the company. , link with the community, environment and responsible consumption.
Among the social commitments that it establishes publicly, it claims to “serve as an example of responsible, honest competitiveness and social commitment for the Mexican pharmaceutical industry.”
Other information that I was able to recover highlights that Electrolit, owned by the company, channeled 600,000 pieces of oral serum to vulnerable groups in 2019.
It was also found that the Stella/PiSA Foundation carries out the program to assist patients with chronic kidney disease on hemodialysis, older adults and promotes community development and volunteering.
Despite the words of the authorities about classifying them as a monopoly of medicine in past six-year terms, PiSA Farmacéutica was consolidated last December, as one of the winning companies in the Consolidated Contracting of medicines and therapeutic goods for the fiscal year 2020, with the award of 15% of the 632 items tendered, according to information from the Treasury.
In the 2020 tender, the SHCP Senior Official's Office invested close to 20 billion pesos, PiSA will take just over 9.9% of those public resources.
According to the bases of the international public tender number LA-006000993-E4-2019, the awarded companies must deliver the medicines until March 2020, at the moment the institutions are operating with the purchase that was made in 2019.
"If a judicial process is presented, it is expected to be concluded, subsequently, Cemefi dialogues with the company, knows in depth the problem in question and on occasions, it has been suggested to the company to stop using the Distinctive" it was reported.
there is any review to remove the ESR Distinction from PiSA Farmacéutica.
PiSA Farmacéutica is a 75-year-old Mexican Chile Mobile Number List corporation that is the largest drug manufacturer in the country, with an annual production of more than one billion units, such as diabetes tablets. In addition to being the only producer of the drug methotrexate, used in children's chemotherapy.
This company also owns Dimesa, one of the three largest distributors in the country and recently accused of abusive practices by monopolizing – along with two other companies – 60% of IMSS and ISSSTE purchases during the previous six-year term.
CSR or not CSR?
The 2017 Sustainability Report of PiSA Farmacéutica, the most recent edition that is disseminated to the public, indicates the company as a corporation that works for its continuous improvement, establishing projects that promote responsible management of the impact of its operation, in an economic aspect, social and environmental.
This Report frames its corporate social responsibility (CSR) actions with brief information, social impact figures, investments and volunteering, in a very general way and without clear details.
It is reported, for example, that the company has a CSR Committee that is made up of small committees that represent the five areas in which they work, which are aligned with those evaluated by Cemefi: business ethics, quality of life in the company. , link with the community, environment and responsible consumption.
Among the social commitments that it establishes publicly, it claims to “serve as an example of responsible, honest competitiveness and social commitment for the Mexican pharmaceutical industry.”
Other information that I was able to recover highlights that Electrolit, owned by the company, channeled 600,000 pieces of oral serum to vulnerable groups in 2019.
It was also found that the Stella/PiSA Foundation carries out the program to assist patients with chronic kidney disease on hemodialysis, older adults and promotes community development and volunteering.
Despite the words of the authorities about classifying them as a monopoly of medicine in past six-year terms, PiSA Farmacéutica was consolidated last December, as one of the winning companies in the Consolidated Contracting of medicines and therapeutic goods for the fiscal year 2020, with the award of 15% of the 632 items tendered, according to information from the Treasury.
In the 2020 tender, the SHCP Senior Official's Office invested close to 20 billion pesos, PiSA will take just over 9.9% of those public resources.
According to the bases of the international public tender number LA-006000993-E4-2019, the awarded companies must deliver the medicines until March 2020, at the moment the institutions are operating with the purchase that was made in 2019.